| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K51831558 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.05 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | -0.097 | 0.05 |
| mRNA | S-Trityl-L-cysteine | GDSC1000 | pan-cancer | AAC | -0.1 | 0.05 |
| mRNA | GW843682X | GDSC1000 | pan-cancer | AAC | -0.1 | 0.06 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | 0.059 | 0.06 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.093 | 0.06 |
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | 0.089 | 0.06 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.057 | 0.06 |
| mRNA | JNK Inhibitor VIII | GDSC1000 | pan-cancer | AAC | -0.065 | 0.06 |
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | 0.059 | 0.06 |